EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Albemarle Corp. (0HC7) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Albemarle Corp. $86.29, price $105, upside -17.9%, quality 54 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Industrials · GB · Home US

AC Some data Sep 24, 2026

Albemarle Corp.

0HC7 · LSE

Overvalued / MonitorQuality is not strong enough to offset the price risk.

!Fair value $86.29 · Overvalued (−17.9%)
!Quality 54/100
!Weak Growth (revenue 5y +10.4 %/yr)
!Loss-making · -4.2% net margin (TTM)
✓Low debt · generates free cash flow
✓1.5% dividend yield · Sustainable
!Mixed vs. peers (8/14)
!Narrow moat 31/100
!Evidence only medium, so the estimate is less certain
!Weak on valuation: 10 out of 100
Watch Albemarle Corp. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$311.02 $50.81 Fair Value $86.29 May 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range $50.81 – $311.02 · fair‑value band $54.68 – $123.57 · the $105.10 price screens above the $86.29 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow Albemarle in your weekly email

Every Wednesday you see whether Albemarle is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Albemarle Corporation provides energy storage solutions worldwide. It operates through three segments: Energy Storage, Specialties, and Ketjen.

Show more

Albemarle Corporation provides energy storage solutions worldwide. It operates through three segments: Energy Storage, Specialties, and Ketjen. The Energy Storage segment offers lithium compounds, including lithium carbonate, lithium hydroxide, and lithium chloride for use in lithium batteries used in consumer electronics and electric vehicles, power grids and solar panels, high performance greases, specialty glass used in consumer appliances and electronics. The Specialties segment provides bromine and highly specialized lithium solutions for various industries, such as energy, mobility, connectivity, and health comprising fire safety compounds; bromine-based specialty chemicals products, including elemental bromine, alkyl bromides, inorganic bromides, brominated powdered activated carbon, and various bromine fine chemicals; lithium specialties, such as butyllithium and lithium aluminum hydride; cesium products for the chemical and pharmaceutical industries; and zirconium, barium, and titanium products for pyrotechnical applications that include airbag initiators. This segment also provides organic synthesis processes in the areas of steroid chemistry and vitamins, and various life science applications, as well as intermediates in the pharmaceutical industry; technical services, including handling and use of reactive lithium products; and recycling services for lithium-containing by-products. The Ketjen segment offers clean fuels technologies, including hydroprocessing catalysts together with isomerization and akylation catalysts; fluidized catalytic cracking catalysts and additives; and performance catalyst solutions comprising organometallics and curatives. It serves grid storage, automotive, aerospace, conventional energy, electronics, construction, agriculture and food, pharmaceuticals and medical device industries. Albemarle Corporation was founded in 1887 and is headquartered in Charlotte, North Carolina.

Stock analysis

Albemarle Corp. (0HC7) currently trades at $105.10, while our model-based Fair Value estimate is $86.29, 17.9% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of $97.59 per share, and 2 of the 13 models we run sit above the $105.10 price.

Bear case: the Growth DCF group reads lowest at $33.56, and 11 of the 13 models stay below the price. Evidence for this calculation is medium.

Scenario range: $54.68 (bear) to $123.57 (bull), the price of $105.10 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 54/100 (solid quality), in the Industrials sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Albemarle Corp. reported revenue of $5.1B in FY2025 versus $3.3B in FY2021, a compound +11.5%/yr. Reported net income was −$511M in FY2025.

Key figures

Market cap $12.4B · P/E ratio 0.5 · EPS (TTM) $2.39 · Dividend yield 1.5% · Net margin −9.9% · Return on equity −1.8% · Return on assets (EBIT) 3.8% · Operating margin 24.8%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).

What moves the price

The share trades about 50% below its 52-week high and 22% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Industrials peers we cover trades at −46% fair-value upside, at −18%, 0HC7 screens cheaper than that median.

Fair Value models

Bear $54.68 Fair Value $86.29 Bull $123.57
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($0.5838 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF $71.67 $117.20 $185.16 76
Growth DCF $72.54 $112.10 $167.21 75
5Y Revenue Exit $23.98 $32.15 $41.04 72
All 13 models by family
DCF Models
FCF DCF $71.67 $117.20 $185.16 76
5Y Revenue Exit $23.98 $32.15 $41.04 72
5Y EBITDA Exit $58.74 $98.07 $143.80 72
10Y Revenue Exit $40.71 $52.52 $66.11 66
10Y EBITDA Exit $62.73 $97.59 $143.75 66
Dividend Discount
Gordon GGM $29.54 $58.87 $89.15 64
DDM Multi-Stage $29.54 $49.47 $62.14 65
Multiples
EV/EBIT $0.9900 $4.74 $8.49 59
EV/EBITDA $58.98 $82.07 $105.15 67
EV/Revenue n/a $1.21 $4.65 50
Asset-Based
NCAV (Graham) $44.88 $60.14 $89.76 54
Growth DCF
Growth DCF $72.54 $112.10 $167.21 75
Rev-Margin DCF $23.98 $33.56 $45.33 71

Open the full fair value analysis →

Notify me when 0HC7 reaches fair value

Put 0HC7 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 54/100

Of which business quality 52 · Market factors (momentum, volatility) 36

Profitability 6
Margins and returns on capital today
Quality Growth 67
Are margins and returns improving?
Cashflow 60
Earnings quality: real cash, not paper profit
Fin. Strength 53
Balance sheet, leverage, solvency risk
Investment 69
Disciplined investing over empire-building
Low Volatility 23
Calm price path (market factor)
Momentum 40
Price trend over the last 3–12 months (market factor)
52W Momentum 44
Distance to the 52-week high (market factor)
Net Issuance 81
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−4.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−11.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.4%
Start year 2020 (pandemic). Over 10 years: +6.2% a year
Revenue growth 32 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.6%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
16.8% (2020) → 1.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+17.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+6.7%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in USD, USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +14.9% a year for the price and +4.2% for the forecasts.
Forecast 2026 (sales)+23.4%
Forecast 2027 (sales)+3.1%
Projected 2028 (sales)+2.9%
Projected 2029 (sales)+2.8%
Projected 2030 (sales)+2.7%

0HC7 screens overvalued: fair value 18% below the price. Compare with Linde plc →

Compare Albemarle Corp. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Specialty Chemicals · 696 stocks

Beats the industry median on 8/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 54 · Above median
Fair Value upside −17.3% · Above median
Profitability
Return on assets 1.6% · Below median
Net margin (TTM) −4.2% · Bottom 25%
Operating margin (TTM) 24.8% · Top 25%
Growth and dividend
Revenue growth 32.7% · Top 25%
Dividend yield (TTM) 1.5% · Above median
Balance sheet
Debt / equity 0.28× · Above median

Valuation Multiplesvs Specialty Chemicals median · lower = cheaper

P/E (TTM) 0.5× · Cheapest 25%
P/B 1.29× · Cheaper than median
P/S (TTM) 2.23× · Pricier than median
P/FCF 17.7× · Cheaper than median
EV/EBITDA 12.5× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)10 · sector 0
FUTURE (revenue growth)100 · sector 54
PAST (return on equity)0 · sector 26
HEALTH (low debt)86 · sector 95
DIVIDEND (yield)31 · sector 29

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Specialty Chemicals stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Linde plc LIN $474.65 $441.72 −7%
The Sherwin-Williams Company SHW $330.44 $151.68 −54%
Ecolab Inc ECL $274.58 $96.56 −65%
Air Products and Chemicals, Inc APD $279.19 $121.30 −57%
Nan Ya Plastics Corporation 1303 238.00 TWD 234.23 TWD −2%
Givaudan SA GIVN CHF 3,360 CHF 1,527 −55%
Sika AG SIKA CHF 183.80 CHF 98.89 −46%
Wanhua Chemical Group 600309 ¥69.45 ¥68.03 −2%
DSM-Firmenich AG DSFIR CHF 92.30 CHF 29.70 −68%
Asian Paints Limited ASIANPAINT ₹2,444 ₹1,479 −39%

Explore undervalued stocks

More undervalued Industrials stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Albemarle Corp. · Fair Value
$86.29 −18%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Albemarle Corp. Fair Value". https://www.fairvalue-calculator.com/stock/0HC7

Frequently asked questions

Is Albemarle Corp. (0HC7) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $86.29 versus a price of $105.10, about −18% upside (overvalued).
What is the fair value of 0HC7?
Our model-based fair value for Albemarle Corp. is $86.29 (as of Sep 24, 2026), built from audited fundamentals. The current price: $105.10.
What is the quality score of 0HC7?
Albemarle Corp. has a Quality Score of 54/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Albemarle Corp. (0HC7)?
Our model-based price target is the fair value of $86.29 (as of Sep 24, 2026) from 13 valuation models. Cautious scenario $54.68, optimistic scenario $123.57. It is a calculation from audited fundamentals, not an analyst target.
What is the Albemarle Corp. stock forecast for 2026?
Our models put fair value at $86.29, about −18% upside versus a price of $105.10 (overvalued). Cautious scenario $54.68, optimistic scenario $123.57. The calculation is refreshed regularly with new filings.
What is the revenue of Albemarle Corp. (0HC7)?
Albemarle Corp. reported trailing-twelve-month revenue of about $5.5B (latest available figure, as of Sep 24, 2026).
Does Albemarle Corp. pay a dividend?
Albemarle Corp. currently shows a dividend yield of about 1.54% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Albemarle Corp. (0HC7)?
For today's price to be fair in a discounted-cash-flow model, Albemarle Corp. would have to grow free cash flow by +17.6 % per year for five years (discount rate 11.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +10.5 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 0HC7 use?
Our models discount Albemarle Corp. at 11.2 %: a base by market capitalisation (unknown), damped by beta 1.35, country premium for United Kingdom. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Albemarle Corp. that is +17.6 % per year a year over ten years, using the same discount rate (11.2 %) and the same formula as our fair value.
How much growth has Albemarle Corp. (0HC7) delivered so far?
Over the past 5 years revenue at Albemarle Corp. grew +10.5 % a year. The price currently implies +17.6 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Albemarle Corp. (0HC7) growing?
The median revenue growth in the sector is +7.0 % a year. That is the yardstick for the growth priced into Albemarle Corp. (+17.6 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Albemarle Corp. (0HC7)?
The free-cash-flow yield on the price is 4.23 %: that much free cash flow Albemarle Corp. produces per unit of market value. When it exceeds the discount rate of our models (11.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Albemarle Corp. (0HC7)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Albemarle Corp. it is $86.29 per share (as of Sep 24, 2026), against a price of $105.10. It is the blended result of 13 valuation models (cash flow, earnings, asset, dividend).
Is Albemarle Corp. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 0HC7 trades above its calculated fair value: price $105.10, fair value $86.29, a gap of about −18% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0HC7?
No. The price is what the market pays today ($105.10); the fair value is what the company's own numbers justify ($86.29). For Albemarle Corp. the two are $18.81 per share apart. That gap is exactly why we show both numbers side by side.
How much is Albemarle Corp. worth?
The market values Albemarle Corp. at about $12.4B (market capitalisation, as of Sep 24, 2026). Per share that is $105.10; our models calculate a fair value of $86.29 per share.
What do the bullish and bearish scenarios say about 0HC7?
Our models span a range for Albemarle Corp.: cautious scenario $54.68, base $86.29, optimistic $123.57 per share (as of Sep 24, 2026, price $105.10). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 0HC7?
Albemarle Corp. trades at a price-to-earnings ratio of 0.5 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $86.29 is built from several models across several years. Other multiples: P/B 1.3, P/S 2.2, EV/EBITDA 12.5.
How solid is the balance sheet of Albemarle Corp. (0HC7)?
Balance-sheet figures for Albemarle Corp. (as of Sep 24, 2026): return on equity −1.8%, debt of 0.28 per unit of equity. They feed the Quality Score of 54/100, which measures business quality independently of the share price.
How far is 0HC7 from its 52-week high?
Albemarle Corp. trades at $105.10, about 50% below its 52-week high of $210.64 and 22% above the low of $86.47 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $86.29 is for.
Which stocks are comparable to Albemarle Corp.?
From the same area (Industrials) we also value Linde plc, The Sherwin-Williams Company, Ecolab Inc, Air Products and Chemicals, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Albemarle Corp. stock attractive at the current price?
The data as of Sep 24, 2026: price $105.10, calculated fair value $86.29 (−18%), Quality Score 54/100, from 13 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0HC7 calculated?
We run Albemarle Corp. through 13 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $86.29, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Albemarle Corp. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Albemarle Corp. (0HC7)?
The closing price on Oct 2, 2026 was $105.10. Our model-based fair value is $86.29, about −18% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Albemarle Corp. right now?
Solid but not exceptional quality (54/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($54.68 to $123.57) leaves room in how you read the outcome.

Key figures of Albemarle Corp.

How large is the market capitalisation of Albemarle Corp. (0HC7)?
The market capitalisation of Albemarle Corp. is $12.4B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Albemarle Corp. (0HC7)?
Earnings per share at Albemarle Corp. are $2.39 (price ÷ EPS = P/E 0.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Albemarle Corp. (0HC7)?
The dividend yield of Albemarle Corp. is 1.5% (payout 67.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Albemarle Corp. (0HC7)?
The net margin of Albemarle Corp. is −9.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Albemarle Corp. (0HC7)?
The return on equity (ROE) of Albemarle Corp. is −1.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Albemarle Corp. (0HC7)?
On an EBIT basis the return on assets of Albemarle Corp. is 3.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Albemarle Corp. (0HC7)?
The operating margin of Albemarle Corp. is 24.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Albemarle Corp. (0HC7)?
Revenue at Albemarle Corp. is growing +32.7% versus a year earlier (3y avg −11.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Albemarle Corp. (0HC7)?
Earnings per share at Albemarle Corp. are growing −66.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Albemarle Corp. (0HC7) carry?
The net debt of Albemarle Corp. is $1.8B (fiscal year 2025, ≈ 2.6 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Albemarle Corp. in the live analysis

One click puts Albemarle Corp. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.